News | January 04, 2010

Stent, Duel Anti-Platelet Study Enrolls First Patient

January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet therapy drug that includes aspirin and Effient.

Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo Inc., manufacturers of Effient, which was recently approved by the FDA. The first patient was enrolled by Joel Cohn, M.D., FACC, at the Ingham Regional Medical Center in Lansing, Mich.

This is the first TAXUS Liberte post-approval study. It will enroll about 4,200 patients at up to 65 U.S. sites. The study will evaluate clinical outcomes in a broad range of patients with coronary artery disease who receive a TAXUS Liberte drug eluting stent followed by the use of aspirin and Effient (prasugrel). The primary endpoint is the rate of cardiac death or myocardial infarction (MI) at 12 months. Secondary endpoints will be analyzed out to five years and include rates of stent thrombosis using the Academic Research Consortium (ARC) definition, target vessel failure (TVF), target vessel revascularization (TVR), MI, bleeding events and stroke.

Boston Scientific plans to contribute data on the first 1,524 eligible patients from the TAXUS Liberte study to the DAPT Study, a collaboration among the FDA, drug and device manufacturers, and the Harvard Clinical Research Institute (HCRI). This four-year public health study will investigate the appropriate duration of dual anti-platelet therapy following drug-eluting stent implantation. HCRI is responsible for the scientific management and independent analysis of the overall study.

For more information: www.bostonscientific.com, www.hcri.harvard.edu

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init